Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of high-dose cisplatin.

W M Holleran1, M W DeGregorio

  • 1Cancer Pharmacology and Pharmacokinetics Laboratory, Children's Cancer Research Institute, Pacific Presbyterian Medical Center, San Francisco.

Investigational New Drugs
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Water extract of gromwell (Lithospermum erythrorhizon) enhances migration of human keratinocytes and dermal fibroblasts with increased lipid synthesis in an in vitro wound scratch model.

Skin pharmacology and physiology·2011
Same author

Kinetic characteristics of acidic and alkaline ceramidase in human epidermis.

Skin pharmacology and physiology·2007
Same author

Skin abnormalities as an early predictor of neurologic outcome in Gaucher disease.

Clinical genetics·2006
Same author

Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.

Cancer chemotherapy and pharmacology·2005
Same author

Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.

Maturitas·2002
Same author

Vitamin C stimulates sphingolipid production and markers of barrier formation in submerged human keratinocyte cultures.

The Journal of investigative dermatology·2001
Same journal

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026
Same journal

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026
Same journal

Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

Investigational new drugs·2026
Same journal

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

Investigational new drugs·2026
Same journal

Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

Investigational new drugs·2026
Same journal

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.

Investigational new drugs·2026
See all related articles

High-dose cisplatin therapy shows increased efficacy in solid tumors by managing kidney toxicity. However, severe neurotoxicity and myelosuppression now limit further dose escalation.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • High-dose cisplatin (200 mg/m2/course) is being investigated for solid tumors.
  • Reduced nephrotoxicity allows for higher cisplatin doses, enhancing efficacy.
  • Increased efficacy is observed when nephrotoxicity is managed effectively.

Purpose of the Study:

  • To review the evolution and current status of high-dose cisplatin therapy.
  • To discuss dose-limiting non-renal toxicities.
  • To explore the relationship between toxicities, pharmacokinetics, and dosing schedules.

Main Methods:

  • Literature review of high-dose cisplatin therapy.
  • Analysis of clinical trial data for efficacy and toxicity.
  • Pharmacokinetic and dosing schedule assessment.

Related Experiment Videos

Main Results:

  • High-dose cisplatin demonstrates improved efficacy in various solid tumors.
  • Nephrotoxicity has been successfully managed, enabling dose escalation.
  • Severe neurotoxicity and myelosuppression have emerged as new dose-limiting factors.

Conclusions:

  • High-dose cisplatin therapy offers enhanced efficacy but faces new toxicity challenges.
  • Understanding neurotoxicity and myelosuppression is crucial for further dose optimization.
  • Pharmacokinetics and dosing schedules are key to managing these new toxicities.